[The stepwise approach of COPD therapy].

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Stable chronic obstructive pulmonary disease (COPD) management aims to alleviate symptoms, enhance exercise tolerance, improve quality of life, and decrease exacerbations.
• Inhaled long-acting bronchodilators, including long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), are key therapeutic agents.

Purpose of the Study:

• To review the pharmacologic and non-pharmacologic strategies for managing stable COPD.
• To compare the efficacy of different inhaled therapies in symptomatic COPD management and exacerbation prevention.

Main Methods:

• Review of current pharmacologic treatments for stable COPD.
• Analysis of comparative effectiveness of LABAs, LAMAs, and inhaled corticosteroids (ICS) in COPD management.
• Inclusion of non-pharmacologic interventions in COPD care.

Main Results:

• LABAs and LAMAs demonstrate comparable efficacy in symptom management.
• LAMAs show superior effectiveness over LABAs in reducing COPD exacerbations.
• Dual bronchodilation with fixed LAMA/LABA combinations is more effective than LAMA monotherapy for exacerbation prevention.
• Triple therapy (LAMA/LABA/ICS) further reduces exacerbations, particularly in patients with elevated blood eosinophils.

Conclusions:

• Pharmacologic therapy for stable COPD should be tailored to individual patient needs, focusing on symptom control and exacerbation reduction.
• Combination therapies, especially triple therapy, offer enhanced benefits for specific COPD patient populations.
• Non-pharmacologic interventions remain crucial components of comprehensive COPD management.